Our long-term objective is to develop effective gene therapies for the treatment of malignancy and melanoma in particular. We have focused both on the discovery of novel genes able to kill tumor cells locally with concomitant activation of specific immune effector cells and on the development of efficient and targeted vectors for their delivery to tumors in situ. The goal of this proposal is to build on work supported by NIH grant RO1 CA 85931. Therein, we successfully developed a novel, highly potent class of genes, the Fusogenic Membrane Glycoproteins (FMG), for gene/ immunotherapy of cancer. Vaccines of FMG-mediated fusing tumor cells significantly increased survival of tumor-bearing mice in both prophylactic and therapy models, leading us to develop a clinical trial at the Mayo Clinic in Stage IV melanoma patients. Consistent with these data, we also described a novel class of subcellular vesicles - syncytiosomes -released during non apoptotic syncytial killing which deliver antigens into dendritic cells for cross presentation to T cells and are effective immunogens in vivo. We also used FMG gene transfer to identify and isolate a completely novel class of small tumor cell/dendritic cell hybrids which cure well established metastatic disease in murine models. Finally, transcriptionally targeted plasmid and retroviral vectors were constructed which combine both local cytotoxic and highly immunostimulatory gene therapy for melanoma. Concurrently, we observed a significant enhancement of virotherapy using replication competent adenoviral vectors in the presence of fusion both in vitro and in vivo. We now propose to build on these data from grant RO1 CA85931. As summarized in Figure 16 of the current proposal, we will 1: Characterize the immunostimulatory components and functions of syncytiosomes; 2: Characterize the interactions of dendritic cells with fusing tumor cells at the level both of uptake of tumor antigen and/or through the formation of tumor cell/DC hybrids to ,generate improved cancer vaccines; 3: Generate both replication incompetent and conditionally replication competent adenoviral vectors with targeted intratumoral expression of FMG to improve both vector performance and therapeutic efficacy. Data from these Specific Aims will allow us to proceed directly to further Phase I/ll clinical trials, either in the context of cell free, syncytiosome-based vaccines, and/or dendritic cell/tumor fusing cell vaccines and/or direct intratumoral injection of melanoma-targeted, FMG expressing adenoviral vectors

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA085931-07
Application #
7036601
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Welch, Anthony R
Project Start
2000-04-01
Project End
2008-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
7
Fiscal Year
2006
Total Cost
$291,668
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kottke, Timothy; Pulido, Jose; Thompson, Jill et al. (2009) Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res 69:7767-74
Hatfield, Paul; Merrick, Alison E; West, Emma et al. (2008) Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother 31:620-32
Merrick, Alison; Diaz, Rosa Maria; O'Donnell, Dearbhaile et al. (2008) Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother 57:897-906
Guedan, S; Gros, A; Cascallo, M et al. (2008) Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther 15:1240-5
Kottke, Timothy; Sanchez-Perez, Luis; Diaz, Rosa Maria et al. (2007) Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 67:11970-9
Diaz, Rosa Maria; Galivo, Feorillo; Kottke, Timothy et al. (2007) Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67:2840-8
Qiao, J; Moreno, J; Sanchez-Perez, L et al. (2006) VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther 13:1457-70
Errington, Fiona; Bateman, Andrew; Kottke, Tim et al. (2006) Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12:1333-41
Fu, Xinping; Tao, Lihua; Jin, Aiwu et al. (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 7:748-54
Ahmed, A; Jevremovic, D; Suzuki, K et al. (2003) Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther 10:1663-71

Showing the most recent 10 out of 15 publications